JAK2 Protein, Active

<strong>JAK2 Protein, Active</strong> <strong>Catalog number:</strong> B2022429 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 10 ug <strong>Molecular Weight or Concentration:</strong> 38.9 kDa <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> −70°C <strong>Keywords:</strong> JAK2 enzyme, Janus kinase 2, JAK2 protein kinase, JAK2 signaling protein, JAK2 active form, JAK2 active enzyme, JAK2 active protein <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kralovics, R., Passamonti, F., Buser, A., et al. (2005). A gain-of-function mutation of JAK2 in myeloproliferative disorders. *New England Journal of Medicine*, 352(17), 1779-1790. 2. Levine, R. L., Wadleigh, M., Cools, J., et al. (2005). Activating mutations in the tyrosine kinase JAK2 in myeloproliferative disorders. *Blood*, 105(3), 1491-1497. 3. James, C., Ugo, V., Le Couédic, J. P., et al. (2005). A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. *Nature*, 434(7037), 1144-1148. 4. Pardanani, A., Lasho, T. L., Jimma, T., et al. (2006). JAK2 V617F mutation in myelofibrosis: a study of 100 patients. *Blood*, 108(10), 3472-3478. 5. Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., et al. (2007). Mutations in JAK2 and MPL in myeloproliferative neoplasms: a review. *Haematologica*, 92(4), 507-514. 6. Tefferi, A., Lasho, T. L., & Pardanani, A. (2009). JAK2 V617F and the myeloproliferative neoplasms: a review. *Nature Reviews Clinical Oncology*, 6(2), 78-85. 7. Kralovics, R., & Passamonti, F. (2010). The role of JAK2 mutations in myeloproliferative neoplasms. *Blood Reviews*, 24(5), 239-248. 8. Guglielmelli, P., & Vannucchi, A. M. (2011). The role of JAK2 mutations in the pathogenesis of myeloproliferative neoplasms. *Current Opinion in Hematology*, 18(2), 85-90. 9. Swerdlow, S. H., Campo, E., Harris, N. L., et al. (2016). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. *World Health Organization.* 10. Verstovsek, S., & Mesa, R. A. (2017). JAK2 inhibitors in myeloproliferative neoplasms: a review. *Blood*, 130(5), 563-570. <a href="JAK2 Protein, Active">https://pubmed.ncbi.nlm.nih.gov/?term=JAK2 Protein, Active</a> <br><strong>Products Related to JAK2 Protein, Active can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>